This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Zhejiang Hisoar Pharmaceutical Co., Ltd.. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: The Innovations of Xianhua Pan
Introduction
Xianhua Pan is a notable inventor based in Taizhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of intermediates for the drug Sitagliptin. His work has implications for diabetes treatment, showcasing the importance of innovation in healthcare.
Latest Patents
Xianhua Pan holds a patent for "Intermediates of Sitagliptin and preparation process thereof." This patent discloses intermediates of Sitagliptin, a preparation process, and a method for synthesizing Sitagliptin using these intermediates. The synthesis process utilizes chiral amino compounds as raw materials, eliminating the need for chiral asymmetric catalytic hydrogenation and avoiding high-pressure hydrogenation.
Career Highlights
Xianhua Pan is associated with Zhejiang Hisoar Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work in the pharmaceutical industry has positioned him as a key figure in the innovation of diabetes medications.
Collaborations
Xianhua Pan collaborates with talented coworkers such as Weijin Li and Qunhui Zhang. Their combined expertise contributes to the success of their projects and enhances the research environment at their company.
Conclusion
Xianhua Pan's contributions to the field of pharmaceuticals, particularly through his patent on Sitagliptin intermediates, highlight the critical role of inventors in advancing medical science. His work exemplifies the impact of innovation on healthcare solutions.